Drug intelligence / Profile preview

TCR-GPC3

Development stage: Preclinical
Lead developer: Adaptimmune Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intracavitary

Overview

TCR-GPC3 is a T cell receptor (TCR) engineered T cell therapy under preclinical development by TCR2 Therapeutics. It is designed to target Glypican-3 (GPC3), a tumor-associated antigen highly expressed in various solid tumors, including hepatocellular carcinoma, hepatoblastoma, ovarian clear cell carcinoma, and squamous cell lung carcinoma, with minimal or no expression in normal adult tissues. This therapy aims to recognize and kill cancer cells presenting GPC3-derived peptides, offering a potential advantage over CAR-T cells by being able to target intracellular GPC3.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on TCR-GPC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCR-GPC3.

Explore the full profile